Company intelligence / Profile preview

Beijing UniteGen

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

SGC001, a First-in-Class (FIC) monoclonal antibody for acute myocardial infarction (AMI), is undergoing Phase I clinical trials pending approvals from US FDA and China NMPA, with expected completion by August 2025.

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: Monoclonal antibodyBispecific antibodyAntibody-drug conjugateAntibody-oligonucleotide conjugate
Industry: Biotech

Beyond the preview

Go deeper on Beijing UniteGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing UniteGen.

Explore the full profile